Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
HRMY 
Harmony Biosciences Holdings (HRMY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: HRMY (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $46.18
1 Year Target Price $46.18
| 5 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -24.88% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.29B USD | Price to earnings Ratio 12.56 | 1Y Target Price 46.18 |
Price to earnings Ratio 12.56 | 1Y Target Price 46.18 | ||
Volume (30-day avg) 9 | Beta 0.8 | 52 Weeks Range 25.52 - 40.93 | Updated Date 12/6/2025 |
52 Weeks Range 25.52 - 40.93 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.17 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 22.48% | Operating Margin (TTM) 27.35% |
Management Effectiveness
Return on Assets (TTM) 13.2% | Return on Equity (TTM) 25.93% |
Valuation
Trailing PE 12.56 | Forward PE 8.09 | Enterprise Value 1626990246 | Price to Sales(TTM) 2.78 |
Enterprise Value 1626990246 | Price to Sales(TTM) 2.78 | ||
Enterprise Value to Revenue 1.9 | Enterprise Value to EBITDA 5.82 | Shares Outstanding 57596358 | Shares Floating 50699194 |
Shares Outstanding 57596358 | Shares Floating 50699194 | ||
Percent Insiders 12.15 | Percent Institutions 88.58 |
Upturn AI SWOT
Harmony Biosciences Holdings
Company Overview
History and Background
Harmony Biosciences Holdings was founded in 2017 with a focus on developing and commercializing treatments for rare neurological disorders. Its primary milestone was the FDA approval and subsequent commercial launch of its flagship product, WAKIXu00ae (pitolisant) tablets, for cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy. The company has since expanded its efforts to explore WAKIX for other indications and to build a robust pipeline.
Core Business Areas
- Pharmaceuticals (Narcolepsy Treatments): Harmony Biosciences is dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders, with a particular emphasis on narcolepsy and its associated symptoms. Their primary focus is on the lifecycle management and expansion of WAKIX.
Leadership and Structure
Harmony Biosciences is led by a team of experienced pharmaceutical executives. The organizational structure is typical of a biotechnology company, with departments dedicated to research and development, commercial operations, regulatory affairs, and corporate functions. Key leadership positions include CEO, CFO, and Chief Medical Officer.
Top Products and Market Share
Key Offerings
- Competitors: Jazz Pharmaceuticals (Xyrem, Xywav),Avadel Pharmaceuticals (Lumieon)
- Product Name 1: WAKIX (pitolisant) tablets. WAKIX is the first and only FDA-approved treatment for cataplexy and EDS in patients with narcolepsy. As of its launch and subsequent market penetration, it has become a leading therapy in its niche. Competitors in the broader narcolepsy treatment landscape include medications for symptom management, but WAKIX offers a novel mechanism of action targeting histamine H3 receptors. Specific market share figures for WAKIX are not publicly disclosed as a percentage but its unique approval makes it a significant player in the narcolepsy market. Revenue generated by WAKIX is the primary driver of Harmony Biosciences's financial performance.
Market Dynamics
Industry Overview
The rare disease pharmaceutical market is characterized by high unmet medical needs, significant R&D investment, and the potential for premium pricing. Companies in this space often focus on niche patient populations with specific genetic or neurological conditions. The narcolepsy market, while considered rare, has seen increasing attention and therapeutic advancements.
Positioning
Harmony Biosciences is positioned as a leader in the rare neurological disease space, particularly in narcolepsy. Its competitive advantage stems from the unique mechanism of action and FDA approval of WAKIX, establishing it as a first-in-class therapy for certain narcolepsy symptoms. The company benefits from a focused commercial strategy and strong relationships with healthcare providers treating these rare conditions.
Total Addressable Market (TAM)
The total addressable market for narcolepsy and related sleep disorders is estimated to be in the billions of dollars globally. Harmony Biosciences, with WAKIX, is targeting a significant portion of this market, specifically patients with narcolepsy experiencing cataplexy and EDS. The company's strategy includes expanding the use of WAKIX to other related conditions, thereby increasing its TAM.
Upturn SWOT Analysis
Strengths
- First-in-class FDA-approved drug (WAKIX) for specific narcolepsy indications.
- Novel mechanism of action targeting histamine H3 receptors.
- Strong commercial execution and market penetration in a niche indication.
- Experienced management team with a track record in pharmaceutical commercialization.
- Focus on rare neurological disorders with significant unmet needs.
Weaknesses
- Heavy reliance on a single product (WAKIX) for revenue.
- Limited pipeline diversity compared to larger pharmaceutical companies.
- Potential for increased competition as the narcolepsy market evolves.
- High cost of drug development and commercialization in rare diseases.
Opportunities
- Expansion of WAKIX indications to other sleep disorders or neurological conditions.
- Geographic expansion of WAKIX sales.
- Development of new formulations or delivery methods for WAKIX.
- Strategic partnerships or acquisitions to bolster the pipeline.
- Increasing awareness and diagnosis rates for narcolepsy.
Threats
- Competition from existing or emerging narcolepsy treatments.
- Pricing pressures and reimbursement challenges.
- Regulatory hurdles for new drug approvals or label expansions.
- Patent expirations and generic competition in the future.
- Unforeseen clinical trial failures or safety concerns.
Competitors and Market Share
Key Competitors
- Jazz Pharmaceuticals (JAZZ)
- Avadel Pharmaceuticals (AVDL)
Competitive Landscape
Harmony Biosciences holds a strong position due to WAKIX being a novel, first-in-class treatment. Its direct competitors focus on other aspects of narcolepsy management, with Jazz Pharmaceuticals being a major player with established products. Avadel Pharmaceuticals is also developing treatments in this space. Harmony's advantage lies in its focused approach and specialized product offering.
Growth Trajectory and Initiatives
Historical Growth: Harmony Biosciences has experienced remarkable historical growth since the commercialization of WAKIX. Its revenue has more than doubled in recent years, driven by strong prescription uptake and market penetration in the narcolepsy space. This growth trajectory highlights the successful commercialization of its core asset.
Future Projections: Analyst projections generally anticipate continued strong revenue growth for Harmony Biosciences, driven by the ongoing expansion of WAKIX's use and potential new indications. The company is expected to further solidify its market leadership in narcolepsy and explore avenues for pipeline expansion.
Recent Initiatives: Recent initiatives have focused on expanding the label of WAKIX, optimizing its commercial strategy, and investing in clinical trials for new potential indications. The company is also actively exploring strategic partnerships and business development opportunities to enhance its long-term growth prospects.
Summary
Harmony Biosciences Holdings is a strong player in the rare disease pharmaceutical market, particularly for narcolepsy, driven by its flagship drug WAKIX. The company has demonstrated impressive revenue growth and profitability, positioning itself as a leader. However, its heavy reliance on a single product and the evolving competitive landscape are areas to watch. Continued investment in pipeline expansion and indication exploration will be crucial for sustained long-term success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Harmony Biosciences Holdings Investor Relations
- Company SEC Filings (10-K, 10-Q)
- Reputable Financial News Outlets
- Pharmaceutical Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Harmony Biosciences Holdings
Exchange NASDAQ | Headquaters Plymouth Meeting, PA, United States | ||
IPO Launch date 2020-08-19 | President, CEO & Director Dr. Jeffrey M. Dayno M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 268 | |
Full time employees 268 | |||
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE). The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.